1145 related articles for article (PubMed ID: 20692814)
21. Sertindole versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; Schmidt F; Lewis R; Kissling W; Leucht S
Cochrane Database Syst Rev; 2009 Apr; (2):CD006752. PubMed ID: 19370652
[TBL] [Abstract][Full Text] [Related]
22. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
23. Akathisia and second-generation antipsychotic drugs.
Kumar R; Sachdev PS
Curr Opin Psychiatry; 2009 May; 22(3):293-99. PubMed ID: 19378382
[TBL] [Abstract][Full Text] [Related]
24. [The use of atypical antipsychotics in the long-term care of schizophrenia].
Limosin F
Encephale; 2006 Dec; 32 Pt 3():S1065-71. PubMed ID: 17356501
[No Abstract] [Full Text] [Related]
25. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.
Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R
Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Melnik T; Soares BG; Puga ME; Atallah AN
Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366
[TBL] [Abstract][Full Text] [Related]
27. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Stip E
Expert Opin Drug Saf; 2012 Sep; 11(5):713-32. PubMed ID: 22913713
[TBL] [Abstract][Full Text] [Related]
28. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B
Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576
[TBL] [Abstract][Full Text] [Related]
29. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
Kuo CJ; Yang SY; Liao YT; Chen WJ; Lee WC; Shau WY; Chang YT; Tsai SY; Chen CC
Schizophr Bull; 2013 May; 39(3):648-57. PubMed ID: 22282455
[TBL] [Abstract][Full Text] [Related]
30. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Leucht S; Pitschel-Walz G; Abraham D; Kissling W
Schizophr Res; 1999 Jan; 35(1):51-68. PubMed ID: 9988841
[TBL] [Abstract][Full Text] [Related]
32. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
33. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
[TBL] [Abstract][Full Text] [Related]
34. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
36. [Psychotropics and weight gain].
Sahli Ch; Bryois Ch
Praxis (Bern 1994); 2004 Aug; 93(35):1393-401. PubMed ID: 15468580
[TBL] [Abstract][Full Text] [Related]
37. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Gao K; Ganocy SJ; Gajwani P; Muzina DJ; Kemp DE; Calabrese JR
J Clin Psychiatry; 2008 Feb; 69(2):302-9. PubMed ID: 18211129
[TBL] [Abstract][Full Text] [Related]
38. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
39. A typical mood stabilizers: a "typical role for atypical antipsychotics.
Malhi GS; Berk M; Bourin M; Ivanovski B; Dodd S; Lagopoulos J; Mitchell PB
Acta Psychiatr Scand Suppl; 2005; (426):29-38. PubMed ID: 16104066
[TBL] [Abstract][Full Text] [Related]
40. [Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Hilger E; Kasper S
Wien Klin Wochenschr; 2000 Dec; 112(24):1031-8. PubMed ID: 11204312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
